Redefining cell line development

Following the launch of Solentim’s new ICON™ instrument and dedicated STUDIUS™ software, the two of which complete the company’s cutting-edge ecosystem, we spoke with Dr Ian Taylor, Chief Business Officer, Solentim, to find out what this means for cell line development and the future of antibody therapeutics.

Read more Redefining cell line development